Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1809 • ACR Convergence 2020
Serum Cytokine Profiling in Systemic Lupus Erythematosus, Analysed Using Unsupervised Machine Learning, Reveals Clinically Relevant Clusters
Fabien Vincent¹, Jannina Ong¹, Alberta Hoi², Sarah Boyd¹, Hieu Nim¹ and Eric Morand³, ¹Monash University, Clayton, Victoria, Australia, ²Monash University, Melbourne, Victoria, Australia, ³Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: SLE is a heterogeneous disease, where a better understanding of molecular differences between patients is needed in order to direct therapy. Existing approaches generally…
Abstract Number: 1826 • ACR Convergence 2020
Maintenance of Efficacy and Safety and Reduction of BILAG Flares with Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 2-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study
Ronald van Vollenhoven¹, Bevra Hahn², George Tsokos³, Peter Lipsky⁴, Robert Gordon⁵, Kaiyin Fei⁶, Kim Hung Lo⁷, Marc Chevrier⁸, Qing Zuraw⁹, Pamela Berry¹⁰, Chetan Karyekar¹⁰ and Shawn Rose¹¹, ¹Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²University of California Los Angeles, Encino, CA, ³Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, ⁴RILITE Foundation, Charlottesville, VA, ⁵Janssen Research & Development, LLC, Chester Springs, PA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Janssen Research & Development, LLC, Spring House, ⁸Janssen Research & Development, LLC, Collegeville, PA, ⁹Janssen Research & Development, LLC, Wayne, PA, ¹⁰Janssen Global Services, LLC, Horsham, PA, ¹¹Janssen Research & Development, LLC, Princeton Junction, NJ
Background/Purpose: Both IL-12 and IL-23 have been implicated in the pathogenesis of SLE. In a phase 2 study, treatment with the anti-IL-12/23 p40 monoclonal antibody…
Abstract Number: 1844 • ACR Convergence 2020
Hydroxychloroquine and QTc Prolongation in a Cohort of SLE Patients
Mayce Haj-Ali¹ and H. Michael Belmont², ¹NYU Langone Health, new york, ²NYU School of Medicine, New York, NY
Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial drug used in the treatment of systemic lupus erythematous (SLE). Cardiac toxicity is very rare in SLE, but has…
Abstract Number: 0247 • ACR Convergence 2020
Lupus Low Disease Activity State Achievement Is Important for Reducing Adverse Outcomes in Pregnant Patients with Systemic Lupus Erythematosus
Ji-Won Kim¹, Ju-Yang Jung¹, Hyoun-Ah Kim¹ and Chang-Hee Suh¹, ¹Ajou university school of medicine, Suwon, Republic of Korea
Background/Purpose: This study aimed to examine the frequency and risk factors of complications during pregnancy in women with systemic lupus erythematosus (SLE).Methods: The medical records…
Abstract Number: 0264 • ACR Convergence 2020
Prevalence and Risk Factors Associated with Isolated Neutropenia in Outpatients with Systemic Lupus Erythematosus
Nouf Alhammadi¹, Murray Urowitz² and Dafna Gladman³, ¹University of Toronto, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Leukopenia in SLE is defined as leukocyte count below 4,000/mm3 on two or more occasions according to the ACR criteria and may include a…
Abstract Number: 0280 • ACR Convergence 2020
Compliance and Validation of Patient Reported Outcome Information Collected from Lupus Patients Using a Mobile Application
Kristy Bell¹, Claire Dykas¹, Hope Rainey¹, Maggy Comberg¹, Mary Mora¹ and Peter Lipsky¹, ¹AMPEL BioSolutions LLC., Charlottesville, VA
Background/Purpose: Patient Reported Outcomes (PROs) can provide critical data in measuring the impact of a disease on an individual as well as the quality of…
Abstract Number: 0298 • ACR Convergence 2020
Local Genetic Ancestry Associations with Clinical Features of Systemic Lupus Erythematosus
Olivia Solomon¹, Cristina Lanata², Cameron Adams¹, Joanne Nititham³, Kim Taylor³, Sharon Chung³, Bernardo Pons-Estel⁴, Teresa Tusié-Luna⁵, Betty Tsao⁶, Eric Morand⁷, Marta Alarcón-Riquelme⁸, Lisa Barcellos¹ and Lindsey Criswell⁹, ¹University of California, Berkeley, Berkeley, CA, ²UCSF, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ⁵Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran and Instituto de Investigaciones Biomédicas de la Universidad Nacional Autónoma de Mexico, Mexico City, Mexico, ⁶Medical University of South Carolina, Charleston, ⁷Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ⁸Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica, Granada (GENYO), Granada, Spain, ⁹Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous clinical manifestations which are known to vary in severity by race. Health disparities in…
Abstract Number: 0472 • ACR Convergence 2020
ApoB:ApoA1 Ratio Could Predict Atherosclerotic Risk in Juvenile-SLE Patients Associated with Altered Interferon Signalling in CD8+ T-cells
George Robinson¹, Kirsty Waddington², Leda Coelewij², Junjie Peng², Meena Naja², Chris Wincup², Anna Radziszewska², Hannah Peckham², David Isenberg², Yiannis Ioannou², Ines Pineda Torra², Coziana Ciurtin² and Elizabeth Jury², ¹University College London, Hertford, United Kingdom, ²University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterised by immune-dysregulation, chronic inflammation, type-I interferon (IFN) signatures and increased cardiovascular disease (CVD) risk…
Abstract Number: 0595 • ACR Convergence 2020
High Satisfaction with Tele-medicine in a New York City Clinic
Tommy Chen¹, Cathy Guo¹, Wei Tang¹, Leila Khalili¹ and Anca Askanase², ¹Columbia University Medical Center, New York, NY, ²Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: The face of medicine is changing with the time. A twenty-first century technological revolution in medicine happened in March 2020 as the COVID-19 pandemic…
Abstract Number: 0847 • ACR Convergence 2020
Impact of Hydroxychloroquine Treatment on Immunologic Markers in SLE Depends on Ethnicity
Laurence Magder¹, Daniel Goldman² and Michelle Petri², ¹University of Maryland, Baltimore, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: SLE patients with certain immunological markers (i.e., anti-DNA, low complement) are at higher risk of lupus nephritis and those with antiphospholipid antibodies are at…
Abstract Number: 0865 • ACR Convergence 2020
Efficacy and Safety of Evobrutinib (M2951) in Adult Patients with Systemic Lupus Erythematosus Who Received Standard of Care Therapy: A Phase II, Randomized, Double-blind, Placebo-controlled Dose Ranging Study
Daniel J Wallace¹, Thomas Dörner², David Pisetsky³, F Jorge Sanchez-Guerrero⁴, Amy Kao⁵, Dana Parsons-Rich⁵, Anand Patel⁶, Yulia Zima⁵, Claire Le Bolay⁷, Karthinathan Thangavelu⁶ and Maria Dall'Era⁸, ¹Cedars-Sinai Medical Center, Beverly Hills, CA, ²DRFZ and Charité University Hospitals, Berlin, Germany, ³Duke University Medical Center, Durham, NC, ⁴University Health Network/Sinai Health system, Toronto, ON, Canada, ⁵EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁶EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, ⁷Merck KGaA, Darmstadt, Germany, ⁸Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: Bruton’s tyrosine kinase (BTK) is involved in signalling pathways known to be important to the pathogenesis of systemic lupus erythematosus (SLE). Evobrutinib is a…
Abstract Number: 0982 • ACR Convergence 2020
Genetics of Avascular Necrosis in Children and Adults with Systemic Lupus Erythematosus
Declan Webber¹, JingJing Cao², Daniela Dominguez³, Dafna Gladman⁴, Andrea Knight⁵, Deborah Levy¹, Lawrence Ng⁶, Andrew Paterson², Zahi Touma⁷, Murray Urowitz⁸, Joan Wither⁹, Earl D. Silverman¹⁰ and Linda Hiraki¹¹, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Genetics & Genome Biology, Research Institute, The Hospital for Sick Children, Toronto, Canada, ³Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada, ⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, Hospital for Sick Children, Toronto, Canada, ⁷University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada, ⁸University Health Network, University of Toronto, Toronto, ON, Canada, ⁹University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ¹⁰Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, ¹¹Division of Rheumatology, The Hospital for Sick Children, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada
Background/Purpose: Genetics have been shown to contribute to risk of avascular necrosis (AVN), a debilitating complication of systemic lupus erythematosus (SLE). Our aim was to…
Abstract Number: 1025 • ACR Convergence 2020
Prevalence Estimates for Systemic Lupus Erythematosus over Four Decades
Ali Duarte-Garcia¹, Mehmet Hocaoglu², Shirley-Ann Osei-Onomah³, Jesse Dabit¹, Sara J. Achenbach³ and Cynthia Crowson⁴, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Prevalence estimates of disease are important for public health planning. The available prevalence estimates of systemic lupus erythematosus (SLE) do not account for changes…
Abstract Number: 1263 • ACR Convergence 2020
Association of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) and Damage Accrual in Long Standing Systemic Lupus Erythematosus
Kaitlin Lima¹, Alexandra Legge², John Hanly², Jungwha Lee³, Jing Song³, Anh Chung³ and Rosalind Ramsey-Goldman⁴, ¹Northwestern University, Chicago, IL, ²Dalhousie University, Halifax, NS, Canada, ³Northwestern University, Chicago, ⁴Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) was recently shown to predict mortality and damage accrual in the SLICC inception cohort. The…
Abstract Number: 1279 • ACR Convergence 2020
Clinical Characteristics and Impact of the COVID-19 Pandemic in Systemic Lupus Erythematosus Patients in a Spanish Tertiary Hospital
Andrea Briones-Figueroa¹, María Jesús García-Villanueva², África Andreu Suárez¹, Marina Tortosa-Cabañas², Ana Corral-Bote², Sandra Garrote-Corral², Javier Bachiller-Corral¹ and Mónica Vázquez¹, ¹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²Hospital Universitario Ramón y Cajal, Madrid, Spain
Background/Purpose: Data about incidence, clinical characteristics and outcome of patients with Systemic Lupus Erythematosus (SLE) with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].